HUYABIO International today announced favorable Phase 1 clinical data for HBI-3000, a novel bioinspired investigational drug with promising antiarrhythmic properties, excellent tolerability and a ...
European decision on approval is expected by Q1 2027If approved, etripamil nasal spray is expected to offer patients a safe and effective ...
An American Heart Association presidential advisory in 2023 introduced a new term: cardiovascular-kidney-metabolic syndrome.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback